Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

– Initial clinical data from CABA-201 treated patients in Phase 1/2 trials for lupus and/or myositis expected in the first half of 2024, with the ...

Related Keywords

Miami ,Florida ,United States ,New York ,Philadelphia ,Pennsylvania ,Wuxi ,Jiangsu ,China ,University Of Pennsylvania ,San Diego ,California ,San Diego Convention Center ,Oxford Biomedica ,Oxford Biomedica Lentivector ,Anup Marda ,Georg Schett ,Steven Nichtberger ,William Gramig ,Manufacturing Organization ,Cabaletta Bio Inc ,Clinical Development ,American College Of Rheumatology ,Nasdaq ,Oxford Biomedica United Kingdom Limited ,Stern Investor Relations Inc ,Drug Administration ,Exchange Commission ,Chief Executive Officer ,Operational Highlights ,Upcoming Anticipated ,Investigational New Drug ,Wuxi Advanced Therapies ,Contract Testing ,Good Manufacturing Practice ,United Kingdom ,Molecular Therapy ,American College ,Cabaletta Bio Scientific Advisory Board ,Carl June ,Innovation Theater ,Cell Therapy ,Annual Evercore ,Cabaletta Bio ,Private Securities Litigation Reform Act ,Orphan Drug Designation ,Fast Track Designation ,Investor Relations ,